Comprehensive Genomic Profiling of 443 Patients with Advanced Renal Cell Carcinoma (rcc) to Reveal Clinically Relevant Genomic Alterations and to Aid in Classification of Rare Subtypes.
Sumanta Kumar Pal,Siraj Mahamed Ali,Zachary Chalmers,Jose A. Karam,Julia Andrea Elvin,Juliann Chmielecki,Roman Yelensky,Eliezer Mendel Van Allen,Doron Lipson,Kai Wang,Andre Poisl Fay,Vincent A. Miller,Phil Stephens,Jeffrey S. Ross,Toni K. Choueiri
DOI: https://doi.org/10.1200/jco.2015.33.15_suppl.4520
IF: 45.3
2015-01-01
Journal of Clinical Oncology
Abstract:e19048 Background: Poor prognosis of advanced NSCLC patients and the promising therapeutic effect of platinum urge the oncologists to evaluate the role of platinum-doublet as second-line chemotherapy and establish the definition of platinum sensitivity in NSCLC. Methods: We retrospectively analyzed 364 advanced NSCLC patients who received platinum-doublet regimens as second-line chemotherapy after platinum-based first-line treatment. Patients were divided into four groups by their time-to-progression (TTP) after first-line chemotherapy: 0-3, 4-6, 7-12, and > 12months group, respectively. Treatment efficacy of patients’ overall survival (OS), progression-free survival (PFS) and response rate (RR), as well as treatment-related toxicity, were compared among the four groups. A prognosis score system and a nomogram were established by Cox proportional hazard model. Results: All patients had Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-1.As part of the platinum-doublet regimen,145(39.8%) patients received taxol, 81(22.3%) received gemcitabine, 99(27.2%) received pemetrexed, 32(8.8%) received vinorelbine, 4(1.1%) received etoposide, and 3(0.8%) received irinotecan.The most frequent grade 3/4 toxicity was neutropenia (20.1%) and nausea/vomiting (3.3%).The median follow-up time was 11.0 months. Patients with TTP > 12 months had significant longer survival than the rest of the group after second-line platinum-rechallenge (HR, 0.809; 95% CI: 0.703-0.931;P = 0.003).Prognostic score was calculated by adding 1 point each for any of the following: TTP > 12 months, age ≤ 60 years, and female, all of which were independent prognostic factors for patient survival (P = 0.015, P = 0.002, P = 0.012, respectively). Median OS were equal to 25.0, 16.0 and 11.0 months for best (2-3 points), intermediate (1 point) and worst (0 point) category, respectively (P < 0.0001). Conclusions: A prognostic score (female, younger than 60 years, or TTP more than 12 months) of 2 or 3 points indicates a good prognosis if advanced NSCLC patients received platinum-rechallenge after disease progression.